Checkmate Pharmaceuticals is a research and development company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging their expertise and the vast body of knowledge in the field of CpG oligonucleotides and is validating an approach that will combine the ability of CpG DNA to activate an anti-tumor T cell response with checkpoint inhibition to overcome a tumor\'s ability to mute the immune response.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/12/15 | $20,000,000 | Series A |
Sofinnova Ventures VenBio | undisclosed |
| 06/16/17 | $27,000,000 | Series B |
F-Prime Capital Partners Sofinnova Ventures VenBio | undisclosed |
| 06/10/20 | $85,000,000 | Series C |
BrightEdge Ventures Clough Capital Partners Decheng Capital F-Prime Capital Partners Longitude Capital Medixci Novo Holdings Omega Funds Sectoral Asset Management Sofinnova Partners VenBio | undisclosed |
